PAPER. Effect of Multiple Nodal Basin Drainage on Cutaneous Melanoma

Size: px
Start display at page:

Download "PAPER. Effect of Multiple Nodal Basin Drainage on Cutaneous Melanoma"

Transcription

1 PAPER Effect of Multiple Nodal Basin Drainage on Cutaneous Melanoma Andrea C. Federico, BA; Anees B. Chagpar, MD; Merrick I. Ross, MD; Robert C. G. Martin, MD; R. Dirk Noyes, MD; James S. Goydos, MD; Peter D. Beitsch, MD; Marshall M. Urist, MD; Stephan Ariyan, MD; Jeffrey J. Sussman, MD; Kelly M. McMasters, MD, PhD; Charles R. Scoggins, MD, MBA; for the Sunbelt Melanoma Trial Hypothesis: The number of nodal basins draining a primary cutaneous melanoma is not an independent predictor of outcome. Design: Post hoc analysis of patients entered into a randomized, prospective study. Setting: Multi-institutional academic and community medical centers. Patients: Patients aged 18 to 70 years with melanoma 1.0 mm or greater Breslow thickness. Interventions: Wide local excision and sentinel lymph node biopsy were performed on all patients; patients with sentinel lymph node metastases underwent completion lymphadenectomy. Patients with multiple nodal basin drainage were compared with those with single nodal basin drainage. Main Outcome Measures: Sentinel lymph node status, locoregional recurrence-free survival, disease-free survival, and overall survival. Results: A total of 2060 patients with single nodal basin drainage (n=1709 [83% of cohort]) were included in the analysis, with a median follow-up of 50 months. On univariate analysis, the group with multiple nodal basin drainage (n=351) was associated with female sex and primary tumor regression (P.001). In addition, multiple nodal basin drainage was associated with truncal primary tumor location (73.2%), while single nodal basin drainage was more common for extremity tumors (50.9%; P.001). On multivariate analysis, there were no differences in the rate of sentinel lymph node metastasis, disease-free survival, or overall survival between the groups. Interestingly, locoregional recurrence was significantly worse in the single nodal basin drainage group (P=.003). Conclusions: Multiple nodal basin drainage does not confer a worse prognosis for patients with cutaneous melanoma. In fact, single nodal basin drainage appears to be associated with a greater risk of locoregional recurrence. Arch Surg. 2008;143(7): Author Affiliations are listed at the end of this article. OF THE CLINICOPATHOlogic factors known to impact outcome for early-stage melanoma, the status of the sentinel lymph node (SLN) appears to be the most important. 1,2 It has become increasingly clear that melanoma arising from the trunk and the head and neck regions have ambiguous drainage patterns, while extremity melanomas more reliably drain to either the inguinal or axillary basins, with occasional popliteal or epitrochlear drainage. 3-6 Interval nodes, or lymph nodes outside traditional nodal basins, are also found in a small proportion of cases Prior data demonstrate that nearly onethird of melanoma tumors arising on the trunk will drain to multiple nodal basins. 13,14 It has been suggested that cutaneous melanoma that has metastasized to more than 1 SLN basin carries a worse prognosis, independent of the actual tumor burden. 15 However, there is conflicting evidence whether drainage to multiple nodal basins (regardless of the presence of nodal metastases) is associated with a worse outcome. Jimenez et al 16 showed that multiple nodal basin drainage for truncal melanoma was associated with a worse survival compared with patients who had drainage to only 1 basin, independent of SLN status. Porter et al 14 also found multiple nodal basin drainage to be independently associated with an increased risk of nodal metastasis. On the other hand, other stud- 632

2 Table 1. Clinical and Pathologic Features of the Patient Population No. (%) of Patients Single Nodal Multiple Nodal Characteristic Basin Drainage Basin Drainage Total Sex F 767 (86.8) 117 (13.2) 884 (42.9) M 942 (80.1) 234 (19.9) 1176 (57.1).001 Median age, y Ethnicity White 1672 (82.9) 345 (17.1) 2017 (98.3) Nonwhite 29 (85.3) 5 (14.7) 5 (1.4).99 Breslow thickness, median, mm Clark level II 30 (83.3) 6 (16.7) 36 (1.8) III 372 (80.9) 88 (19.1) 460 (23.0) IV 1198 (83.5) 237 (16.5) 1435 (71.8) V 57 (85.1) 10 (14.9) 67 (3.4) Histological subtype Superficial spreading melanoma 808 (82.4) 173 (17.6) 981 (49.8) Nodular melanoma 494 (82.5) 105 (17.5) 599 (30.4) Acral lentiginous melanoma 44 (95.7) 2 (4.3) 46 (2.3) Lentigo maligna melanoma 33 (86.8) 5 (13.2) 38 (1.9) Desmoplastic melanoma 27 (75.0) 9 (25.0) 36 (1.8) Other 226 (83.7) 44 (16.3) 270 (13.7) Ulceration Present 453 (82.7) 95 (17.3) 548 (27.0) 1229 (83.0) 251 (17.0) 1480 (73.0) Lymphovascular invasion Present 124 (84.4) 23 (15.6) 147 (8.1) 1374 (82.7) 288 (17.3) 1662 (91.9) Regression Present 159 (73.6) 57 (26.4) 216 (11.7) 1357 (83.6) 266 (16.4) 1623 (88.3) Anatomic site of primary tumor Extremity 869 (94.5) 51 (5.5) 920 (44.7) Trunk 629 (71.0) 257 (29.0) 886 (43.0) Head/neck 210 (83.0) 43 (17.0) 253 (12.3) P Value ies have found that multiple nodal basin drainage does not increase the risk of nodal metastasis or adversely affect prognosis compared with drainage to a single basin. 17,18 Because of the conflicting data regarding the impact of multiple basin drainage, we set out to determine the true effect of multiple nodal basin drainage by analyzing the data from a large prospective, multi-institutional study. METHODS The Sunbelt Melanoma Trial is a prospective, randomized, multiinstitutional study that involved 79 centers in the United States and Canada. Each site s institutional review board approved the study, and all participants gave signed informed consent. Patients were eligible if they were aged from 18 to 70 years, had a cutaneous melanoma 1 mm or greater in Breslow thickness, and did not have clinical evidence of nodal or distant metastases. All patients underwent wide local excision of the primary melanoma and SLN biopsy (the procedural details of the Sunbelt Melanoma Trial have been previously described 19 ). The Sunbelt Melanoma Trial was designed to evaluate the role of reverse transcriptase polymerase chain reaction for ultrastaging as well as lymphadenectomy and adjuvant interferon alfa-2b for patients with early nodal metastasis. 20 Randomization was accomplished using a randomized permuted block design with stratification by tumor thickness and ulceration with reassignment to ensure that the number of patients in each arm in each center was roughly balanced. For the current study, patients with complete data were included and divided into 2 groups: those with single nodal basin drainage and those with multiple nodal basin drainage. The 2 groups were compared in terms of SLN metastasis and survival. The survival analyses performed in the 2 groups included locoregional recurrence-free survival (LRRFS), disease-free survival, and overall survival. Locoregional recurrence-free survival included only those recurrences that were local, in transit, or in a regional lymph node basin, while disease-free survival included any type of recurrence of disease. There were 5 distinct lymph node basins used to categorize patients sentinel nodes: the axilla, groin, epitrochlear fossa, popliteal fossa, and neck, which included supraclavicular and parotid lymph nodes. The neck was counted as a single nodal basin for the purposes of this trial, as the primary question of the Sunbelt Melanoma Trial was to determine the role of molecular staging as well as lymphadenectomy and adjuvant interferon. Univariate analyses to determine clinical and pathologic factors correlating with the number of draining basins were performed using likelihood tests for discrete variables and Mann- Whitney tests for the continuous variables. Multivariate analyses were also performed using binary logistic regression for SLN status and the Cox proportional hazard model was used for the survival analyses. Survival curves were generated using the 633

3 Table 2. Multivariate Comparison of Factors Affecting Nodal Metastasis Factor Odds Ratio (95% Confidence Interval) P Value No. of nodal basins Single nodal basin drainage Multiple nodal basin drainage 1.29 ( ).14 Anatomic site of primary tumor Extremity Trunk 1.47 ( ) Head/neck 0.77 ( ).01 Sex F M 0.98 ( ).91 Clark level II III 0.53 ( ) IV 0.90 ( ).01 V 1.61 ( ) Histologic findings Superficial spreading Nodular 1.05 ( ) Acral lentiginous 2.00 ( ) Lentigo maligna 0.23 ( ).29 Desmoplastic 1.33 ( ) Ulceration Present 1.98 ( ).001 Lymphovascular invasion Present 1.86 ( ).01 Breslow thickness 1.15 ( ).001 Age 0.98 ( ).001 Regression Present 1.01 ( ).97 Kaplan-Meier method. P.05 was considered significant. All analyses were performed with SPSS software, version 14.0 (SPSS Inc, Chicago, Illinois). RESULTS STUDY POPULATION A total of 2060 patients were included in this analysis. There were 884 (42.9%) women and 1176 (57.1%) men, with a median age of 50.5 years. The median follow-up time was 50 months. Nine hundred twenty patients (44.7%) had extremity melanomas, 886 (43.0%) had truncal melanomas, and 253 (12.3%) had melanoma of the head and neck. There were 1709 (83%) patients with single nodal basin drainage and 351 (17%) patients with multiple nodal basin drainage. Of the patients with multiple-basin drainage, 267 (76.1%) did not have metastases in the SLN, while 84 (23.9%) had tumor-positive SLNs. Of the patients with tumor-positive SLNs, 53 (63.1%) had a single positive SLN, 26 (31.0%) had 2 positive SLNs, 4 (4.8%) had 3 positive SLNs, and 1 (1.2%) had 4 positive SLNs. Of the 31 patients with 2 or more positive SLNs, 21 (67.7%) had a positive SLN in 2 separate nodal basins, while the other 10 patients had nodal metastases in only 1 of the mapped basins. Only 3 patients (0.9%) in the multiple nodal basin drainage group had melanomas that drained to more than 2 lymph node basins. CLINICOPATHOLOGIC FEATURES There were several interesting differences between the 2 groups with regards to clinicopathologic features (Table 1). Women were more likely to have single nodal basin drainage than men (P.001). The anatomic site of the primary tumor was also different between the 2 groups (P.001). Extremity tumors were much more likely to drain to a single nodal basin (94.5% of cases), while the truncal melanomas were more likely to drain to multiple basins (29.0% of cases). Despite the fact that head and neck melanomas typically have ambiguous drainage and are believed to frequently exhibit drainage to multiple basins, head and neck tumors fell between the other 2 sites with 17.0% in the multiple nodal basin drainage group. NUMBER OF DRAINING NODAL BASINS AND SLN STATUS OR SURVIVAL The number of draining nodal basins was found to affect the rate of SLN metastasis by univariate analysis (P=.02); however, this difference did not remain significant on multivariate analysis (P=.14) (Table 2). The number of draining SLNs was not associated with the risk of nodal metastasis (P=.19). Interestingly, when considering only patients with a positive SLN, multiple nodal basin drainage was associated with a higher risk of having more than 1 metastatic node (37% vs 21%; P=.004). Kaplan-Meier survival curves showed that LRRFS was significantly worse in the single nodal basin drainage group (P=.003), but the number of draining nodal basins did not affect either disease-free survival (P=.78) or overall survival (P=.22) (Figure). The number of draining nodal basins remained a significant predictor of LRRFS on multivariate Cox regression analysis (Table 3). Additionally, analysis by the number of nodal basins containing metastatic disease again demonstrates that patients with single nodal basin drainage have a worse outcome than patients with multiple nodal basin drainage in terms of LRRFS (odds ratio, 0.344; 95% confidence interval, ; P=.001), but there was no difference in diseasefree survival or overall survival. Further stratified analysis to determine the effect modification between tumor location and the number of draining nodal basins was conducted using a proportional hazards model. This revealed that for patients with extremity melanoma, the number of nodal basins was not significant (P=.79). However, for patients with truncal melanoma, the number of draining nodal basins was significant (P=.01), indicating that anatomic site is an effect modifier. Likewise, sex is an effect modifier in the proportional hazards model (men, P=.02; women, P=.76). There were 131 patients who had melanomas recur either locally or in transit; 39.7% of these patients had a positive SLN at the time of treatment for their primary melanoma, and they were more likely to have had single nodal basin drainage (P=.02). There were 634

4 Survival Proportion Survival Proportion Survival Proportion A B C MNBD SNBD Local and regional recurrence-free survival Disease-free survival Overall survival Time, mo Figure. Local and regional recurrence-free survival (P=.003) (A), disease-free survival (P=.78) (B), and overall survival (P=.22) (C), comparing single and multiple nodal basin drainage groups. MNBD indicates multiple nodal basin drainage; SNBD, single nodal basin drainage. 58 local/in-transit recurrences in patients with extremity melanomas compared with 51 local/in-transit recurrences in patients with trunk melanomas (P=.69). Given that only 5.5% of extremity melanomas drained to multiple basins, analysis to determine the impact of nodal basin drainage pattern on LRRFS for truncal and head/ neck primary sites was conducted. Patients with nonextremity tumors that drained to a single nodal basin had a worse 5-year LRRFS (86.3%) compared with 95.7% in Table 3. Multivariate Analysis of Factors Associated With Locoregional Recurrence-Free Survival Factor Odds Ratio (95% Confidence Interval) P Value No. of nodal basins Single nodal basin drainage Multiple nodal basin drainage 0.49 ( ).04 Anatomic site of primary tumor Extremity Trunk 1.16 ( ) Head/neck 1.36 ( ).62 Sex F M 1.13 ( ).58 Clark level II III 0.32 ( ) IV 0.56 ( ).33 V 0.53 ( ) Histologic findings Superficial spreading Nodular 1.25 ( ) Acral lentiginous 4.50 ( ) Lentigo maligna 1.39 ( ).01 Desmoplastic 0.69 ( ) Ulceration Present 2.70 ( ).001 Lymphovascular invasion Present 0.86 ( ).66 Breslow thickness 1.14 ( ).01 Age 1.01 ( ).52 Regression Present 1.07 ( ).85 those whose tumors drained to multiple basins (P.001). There were 52 patients who had melanomas recur in a previously mapped nodal basin; 3.8% of these patients had a positive SLN. The number of draining nodal basins did not impact the risk of recurrence in a previously mapped basin (P=.19). Nineteen patients developed metastatic disease in a previously unmapped nodal basin; 47.4% of these patients had a positive SLN detected at the time of their melanoma treatment. Again, there was not a difference between single nodal basin drainage and multiple nodal basin drainage (P=.06). COMMENT Predicting the precise lymphatic drainage of melanomas remains elusive, despite efforts by investigators to map these lines with reasonable certainty A recent attempt to classify drainage patterns into distinct groups demonstrated that 6% of all primary melanoma tumors had drainage to multiple lymph node basins, and the tumor location with the highest rate of multiple nodal basin drainage was the trunk. 24 Other studies have found that a greater percentage of melanomas drain to multiple basins, with a range of approximately 30% to 40%. 14,16 635

5 In the present study, 17% of melanomas exhibited multiple nodal basin drainage. Given the impact that lymph node biology has on the prognosis of melanoma, investigators have been interested in patients whose tumors drain to multiple basins. Several studies looked at patients with multiple nodal basin drainage to determine if there was a survival difference compared with those with single nodal basin drainage. These smaller studies were limited to patients with melanomas located on the trunk. The rationale for this approach is that the trunk is the most common location for multiple basin drainage We decided to expand our study cohort to include all anatomic sites. Our data demonstrate that drainage to a single nodal basin is a risk factor for local, in-transit, and regional recurrence. Additionally, those patients presenting with metastatic disease in the lymph nodes that drained to a single basin had a worse LRRFS than node-positive patients whose disease drained to multiple basins. These data did not translate into differences in overall survival, however. One hypothesis that potentially explains this phenomenon is that some patients might have significant endolymphatic tumor burden at the time of the lymphoscintigram and that these clogged lymphatic channels may (1) limit drainage to a single regional basin and (2) place them at a higher risk for local and in-transit recurrence. This theory is supported (at least partially) by the finding that patients with single nodal basin drainage had a higher risk of local and in-transit recurrence. There was no difference in the risk of local or in-transit recurrence between extremity and trunk melanomas. However, when we considered only the nonextremity tumors (which comprised nearly 95% of the patients with tumors that drained to multiple basins), we found that these patients did have a higher risk of local and in-transit recurrence based on the number of draining nodal basins. It makes sense intuitively that patients with metastatic melanoma draining to more than 1 lymph node basin would confer a worse prognosis, independent of the aggregate tumor burden, as shown by Dale et al. 15 They postulated that this may indicate that the tumor is more aggressive in its inherent ability to spread, thus conferring a poorer prognosis. 15 Perhaps the malignant cells seed other locations as they travel through the lymphatics, thus resulting in more metastatic deposits. However, debate remains about whether drainage to more than 1 lymph node basin alone, regardless of SLN status, affects survival. Jimenez et al 16 found that multiple nodal basin drainage was an independent risk factor for poorer survival, even when only patients with negative SLNs were analyzed. Porter et al 14 found that multiple nodal basin drainage was independently associated with an increased risk of nodal metastases. Positive SLN status in turn imposes an increased risk of melanoma-related death. 2 In contrast, other investigators have found no association between multiple nodal basin drainage and melanoma outcome. 17,18 Our data do not support the notion that melanomas draining to multiple nodal basins are worse than those draining to a single basin. In fact, we found the opposite. One notable difference between the single and multiple nodal basin drainage groups was that there was a greater proportion of men in the latter group, in keeping with results from other studies Furthermore, men had a greater proportion of truncal melanomas than women. Additionally, and not surprisingly, the multiple nodal basin drainage group had the largest percentage of trunk melanomas. It is interesting that there was no difference in the number of patients with head and neck melanomas between the 2 groups. We found no significant association between multiple nodal basin drainage and SLN status, disease-free survival, or overall survival. The single nodal basin drainage group was found to have worse LRRFS than the multiple nodal basin drainage group, however, as seen on our multivariate analysis. This analysis included anatomic site as a covariate, making the possibility that this difference was due to the location of the tumor unlikely. From these data, we can conclude that the presence of multiple nodal basin drainage does not confer a worse prognosis. Accepted for Publication: February 15, Author Affiliations: Division of Surgical Oncology, Department of Surgery, University of Louisville, James Graham Brown Cancer Center and Center for Advanced Surgical Technologies of Norton Hospital, Louisville, Kentucky (Ms Federico and Drs Chagpar, Martin, McMasters, and Scoggins); Department of Surgical Oncology, University of Texas M. D. Anderson Cancer Center, Houston (Dr Ross); Departments of Surgery, LDS Hospital, Salt Lake City, Utah (Dr Noyes); Cancer Institute of New Jersey, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick (Dr Goydos), Dallas Surgical Group, Dallas, Texas (Dr Beitsch), University of Alabama, Birmingham (Dr Urist); Melanoma Unit of the Yale Cancer Center, Department of Surgery, Yale University School of Medicine, New Haven, Connecticut (Dr Ariyan); and Department of Surgery, University of Cincinnati, Cincinnati, Ohio (Dr Sussman). Correspondence: Charles R. Scoggins, MD, MBA, Division of Surgical Oncology, Department of Surgery, University of Louisville School of Medicine, Louisville, KY (charles.scoggins@louisville.edu). Author Contributions: Study concept and design: McMasters and Scoggins. Acquisition of data: Federico, Ross, Noyes, Goydos, Beitsch, and Scoggins. Analysis and interpretation of data: Federico, Chagpar, Ross, Martin, Urist, Ariyan, Sussman, and Scoggins. Drafting of the manuscript: Federico and Scoggins. Critical revision of the manuscript for important intellectual content: Chagpar, Ross, Martin, Noyes, Goydos, Beitsch, Urist, Ariyan, Sussman, McMasters, and Scoggins. Statistical analysis: Chagpar. Administrative, technical, and material support: Federico and Sussman. Study supervision: Chagpar, Urist, McMasters, and Scoggins. Financial Disclosure: None reported. Previous Presentation: This paper was presented at the 2007 Annual Meeting of the Western Surgical Society; November 5, 2007; Colorado Springs, Colorado; and is published after peer review and revision. The discus- 636

6 sions that follow this article are based on the originally submitted manuscript and not the revised manuscript. Additional Contributions: We sincerely thank Deborah Hulsewede, CCRP, Sherrie Matthews, CCRP, Wanda Greenwell, RN, Pam Harlan, RN, and Ivan Deyahs for their dedication and hard work in keeping the Sunbelt Melanoma Trial up and running. We also express gratitude to Advertek Inc for the expert data management for the Sunbelt database. REFERENCES 1. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19(16): Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol. 1999;17(3): Uren RF, Howman-Giles R, Thompson JF. Patterns of lymphatic drainage from the skin in patients with melanoma. J Nucl Med. 2003;44(4): Thompson JF, Uren RF, Shaw HM, et al. Location of sentinel lymph nodes in patients with cutaneous melanoma: new insights into lymphatic anatomy. JAm Coll Surg. 1999;189(2): Norman J, Cruse CW, Espinosa C, et al. Redefinition of cutaneous lymphatic drainage with the use of lymphoscintigraphy for malignant melanoma. Am J Surg. 1991;162(5): O Brien CJ, Uren RF, Thompson JF, et al. Prediction of potential metastatic sites in cutaneous head and neck melanoma using lymphoscintigraphy. Am J Surg. 1995;170(5): Hunt JA, Thompson JF, Uren RF, Howman-Giles R, Harman CR. Epitrochlear lymph nodes as a site of melanoma metastasis. Ann Surg Oncol. 1998;5(3): Leong SP, Achtem TA, Habib FA, et al. Discordancy between clinical predictions vs lymphoscintigraphic and intraoperative mapping of sentinel lymph node drainage of primary melanoma. Arch Dermatol. 1999;135(12): McMasters KM, Chao C, Wong SL, et al. Interval sentinel lymph nodes in melanoma. Arch Surg. 2002;137(5): Roozendaal GK, de Vries JD, van Poll D, et al. Sentinel nodes outside lymph node basins in patients with melanoma. Br J Surg. 2001;88(2): Thompson JF, Hunt JA, Culjak G, Uren RF, Howman-Giles R, Harman CR. Popliteal lymph node metastasis from primary cutaneous melanoma. Eur J Surg Oncol. 2000;26(2): Uren RF, Howman-Giles R, Thompson JF, et al. Interval nodes: the forgotten sentinel nodes in patients with melanoma. Arch Surg. 2000;135(10): McMasters KM, Sondak VK, Lotze MT, Ross MI. Recent advances in melanoma staging and therapy. Ann Surg Oncol. 1999;6(5): Porter GA, Ross MI, Berman RS, Lee JE, Mansfield PF, Gershenwald JE. Significance of multiple nodal basin drainage in truncal melanoma patients undergoing sentinel lymph node biopsy. Ann Surg Oncol. 2000;7(4): Dale PS, Foshag LJ, Wanek LA, Morton DL. Metastasis of primary melanoma to two separate lymph node basins: prognostic significance. Ann Surg Oncol. 1997; 4(1): Jimenez RE, Panageas K, Busam KJ, Brady MS. Prognostic implications of multiple lymphatic basin drainage in patients with truncal melanoma. J Clin Oncol. 2005;23(3): McHugh JB, Su L, Griffith KA, et al. Significance of multiple lymphatic basin drainage in truncal melanoma patients undergoing sentinel lymph node biopsy. Ann Surg Oncol. 2006;13(9): Jacobs IA, Chang CK, Salti GI. Significance of dual-basin drainage in patients with truncal melanoma undergoing sentinel lymph node biopsy. J Am Acad Dermatol. 2003;49(4): McMasters KM, Reintgen DS, Ross MI, et al. Sentinel lymph node biopsy for melanoma: how many radioactive nodes should be removed? Ann Surg Oncol. 2001;8(3): McMasters KM, Noyes RD, Reintgen DS, et al. Lessons learned from the Sunbelt Melanoma Trial. J Surg Oncol. 2004;86(4): Haagensen CD, Feind CR. The Lymphatics in Cancer. Philadelphia, PA: W.B. Saunders; Sappey MPC. Anatomie, physiologie, pathologie des vaisseaux lymphatiques consideres chez l homme et les vertebres. Paris, France: DeLahaye A, Lecrosnier E; Sugarbaker EV, McBride CM. Melanoma of the trunk: the results of surgical excision and anatomic guidelines for predicting nodal metastasis. Surgery. 1976; 80(1): Leong SP, Morita ET, Sudmeyer M, et al. Heterogeneous patterns of lymphatic drainage to sentinel lymph nodes by primary melanoma from different anatomic sites. Clin Nucl Med. 2005;30(3): Balch CM, Soong SJ, Bartolucci AA, et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg. 1996;224(3): Garbe C, Buttner P, Bertz J, et al. Primary cutaneous melanoma: prognostic classification of anatomic location. Cancer. 1995;75(10): Schuchter L, Schultz DJ, Synnestvedt M, et al. A prognostic model for predicting 10-year survival in patients with primary melanoma: The Pigmented Lesion Group. Ann Intern Med. 1996;125(5): Caraco C, Marone U, Celentano E, Botti G, Mozzillo N. Impact of false-negative sentinel lymph node biopsy on survival in patients with cutaneous melanoma. Ann Surg Oncol. 2007;14(9): Yancovitz M, Finelt N, Waycha MA, et al. Role of radiologic imaging at the time of initial diagnosis of stage T1b-T3b melanoma. Cancer. 2007;110(5): Aloia TA, Gershenwald JE, Andtbacka RH, et al. Utility of computed tomography and magnetic lymph node-positive melanoma. J Clin Oncol. 2006;24(18): DISCUSSION Jeffrey E. Lee, MD, Houston, Texas: The data that Dr Scoggins and his coauthors have presented from the Sunbelt Melanoma Trial represent another example of how surgeons from academic and community centers who collaborate to answer 1 important clinical question can continue to use the same patient cohort to answer other important questions for years and even decades afterwards. The current study addresses a potentially significant issue not imagined in the original Sunbelt Trial: are patients whose primary melanomas drain to multiple regional nodal basins at increased risk for metastasis, recurrence, or death from their disease? 14 The study is a large one, involving more than 2000 patients. The patients were followed prospectively, and the median follow-up of the group is now relatively mature at more than 4 years. Since the patients were treated at a variety of institutions, the data can probably be taken to represent an aggregate standard of care, rather than being biased by the approach of any single institution. The authors primary conclusion, that patients whose melanomas drain to multiple regional nodal basins are not at elevated risk for nodal metastasis, recurrence, or death from their disease, appears sound. However, the intriguing and counterintuitive observation that patients with single nodal basin drainage (particularly patients with trunk primaries) are more likely to develop local-regional recurrence than patients with multiple nodal basin drainage raises several important questions. First, what were the specific patterns of failure of the single vs multiple nodal basin drainage groups? If singlenode basin patients with trunk primaries more commonly recurred in basins not originally mapped (eg, the opposite axilla) or recurred in a previously mapped basin, it would suggest that such patients may have undergone incomplete initial mapping procedures. If such a pattern were identified, it would suggest a follow-up question: Was single-basin drainage from a trunk primary more commonly seen at some institutions than others? Second, can the authors provide a suggested biologic mechanism for the observation? Anecdotally, some patients with advanced primary melanomas will exhibit poor lymphatic drainage on lymphoscintigraphy or lymphatic mapping. Such patients may have multiple involved nodes, but a choked lymphatic system may prevent adequate sentinel node identification. Could the single-nodal basin patients be at increased risk for regional recurrence because of a less extreme example of a regional metastasis that closes the door behind it and thereby 637

7 prevents complete identification of regional disease by lymphatic mapping? 28 Third and finally, how would the authors suggest the findings be incorporated into clinical practice? Should patients with trunk melanomas that drain to only a single-nodal basin be subjected to more aggressive evaluation or follow-up? Should such a patient have a preoperative US [ultrasound] of all potentially at-risk nodal basins, or is lymphoscintigraphy still sufficient? Should PET [positron-emission tomography] imaging be used? Should we follow such patients postoperatively with US or PET? 29,30 I congratulate the authors on a fine study. Dr Scoggins: We were very interested to find that patients with single nodal basin drainage actually had a shorter local and regional recurrence-free survival. You re right, it is counterintuitive, until you look a little further and see that the majority of those patients with single nodal basin drainage indeed had extremity lesions. The nonextremity patients with single basin drainage do seem to have a higher incidence of local and in-transit recurrence as opposed to recurrence in a previously mapped basin. Whether or not there is a biological mechanism that explains this phenomenon is a very interesting question. The hypothesis that you alluded to regarding choked lymphatic channels is an interesting one and perhaps carries some validity. Another possibility was raised recently by authors who demonstrated that patients with melanoma lesions that drain via multiple lymphatic channels, albeit single nodal basin, also have a worse prognosis. We did not capture number of draining lymphatic channels as part of the Sunbelt Trial, but those data would be intriguing to go back and look into. Whether or not clinical practice should be changed or altered for patients with truncal melanomas draining to a solitary basin is a difficult one to know whether or not PET scan[s] done more frequently would pick up microscopic or very small disease in a patient who is ultimately deemed to in-transit or satellite failure is unknown and it certainly raises a question, and possibly one that could impact financially as well. Financial Disclosure: None reported. Call for Papers D uring 2008, we are soliciting manuscripts on disparities in health care. The editorial board has selected this topic as our year-long theme. We will publish these manuscripts in each issue as the manuscripts are submitted and accepted. Please indicate in your cover letter that your manuscript is to be considered for this theme. 638

PAPER. Prognostic Information From Sentinel Lymph Node Biopsy in Patients With Thick Melanoma

PAPER. Prognostic Information From Sentinel Lymph Node Biopsy in Patients With Thick Melanoma PAPER Prognostic Information From Sentinel Lymph Node Biopsy in Patients With Thick Melanoma Charles R. Scoggins, MD, MBA; Adrianne L. Bowen, MD; Robert C. Martin II, MD, PhD; Michael J. Edwards, MD; Douglas

More information

Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival

Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival MOLECULAR AND CLINICAL ONCOLOGY 7: 1083-1088, 2017 Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival FARUK TAS

More information

ORIGINAL ARTICLE. Clinical Node-Negative Thick Melanoma

ORIGINAL ARTICLE. Clinical Node-Negative Thick Melanoma ORIGINAL ARTICLE Clinical Node-Negative Thick Melanoma George I. Salti, MD; Ashwin Kansagra, MD; Michael A. Warso, MD; Salve G. Ronan, MD ; Tapas K. Das Gupta, MD, PhD, DSc Background: Patients with T4

More information

ORIGINAL ARTICLE PROGNOSTIC IMPLICATION OF SENTINEL LYMPH NODE BIOPSY IN CUTANEOUS HEAD AND NECK MELANOMA

ORIGINAL ARTICLE PROGNOSTIC IMPLICATION OF SENTINEL LYMPH NODE BIOPSY IN CUTANEOUS HEAD AND NECK MELANOMA ORIGINAL ARTICLE PROGNOSTIC IMPLICATION OF SENTINEL LYMPH NODE BIOPSY IN CUTANEOUS HEAD AND NECK MELANOMA Benjamin E. Saltman, MD, 1 Ian Ganly, MD, 2 Snehal G. Patel, MD, 2 Daniel G. Coit, MD, 3 Mary Sue

More information

SENTINEL LYMPH node (SLN) biopsy has become

SENTINEL LYMPH node (SLN) biopsy has become COMMENTARY Sentinel Lymph Node Biopsy for Melanoma: Controversy Despite Widespread Agreement By Kelly M. McMasters, Douglas S. Reintgen, Merrick I. Ross, Jeffrey E. Gershenwald, Michael J. Edwards, Arthur

More information

Malignant Melanoma in Turkey: A Single Institution s Experience on 475 Cases

Malignant Melanoma in Turkey: A Single Institution s Experience on 475 Cases Malignant Melanoma in Turkey: A Single Institution s Experience on 475 Cases Faruk Tas, Sidika Kurul, Hakan Camlica and Erkan Topuz Institute of Oncology, Istanbul University, Istanbul, Turkey Received

More information

Increasing Age Is Associated with Worse Prognostic Factors and Increased Distant Recurrences despite Fewer Sentinel Lymph Node Positives in Melanoma

Increasing Age Is Associated with Worse Prognostic Factors and Increased Distant Recurrences despite Fewer Sentinel Lymph Node Positives in Melanoma Increasing Age Is Associated with Worse Prognostic Factors and Increased Distant Recurrences despite Fewer Sentinel Lymph Node Positives in Melanoma A. J. Page, Emory University A. Li, Emory University

More information

1

1 www.clinicaloncology.com.ua 1 Prognostic factors of appearing micrometastases in sentinel lymph nodes in skin melanoma M.N.Kukushkina, S.I.Korovin, O.I.Solodyannikova, G.G.Sukach, A.Yu.Palivets, A.N.Potorocha,

More information

Is There a Benefit to Sentinel Lymph Node Biopsy in Patients With T4 Melanoma?

Is There a Benefit to Sentinel Lymph Node Biopsy in Patients With T4 Melanoma? Is There a Benefit to Sentinel Lymph Node Biopsy in atients With T4 Melanoma? Csaba Gajdos, MD 1 ; Kent A. Griffith, MH, MS 2 ; Sandra L. Wong, MD 1 ; Timothy M. Johnson, MD 1,3 ; Alfred E. Chang, MD 1

More information

Sentinel Lymph Node Status is the Most Important Prognostic Factor in Patients With Melanoma of the Scalp

Sentinel Lymph Node Status is the Most Important Prognostic Factor in Patients With Melanoma of the Scalp The Laryngoscope VC 2013 The American Laryngological, Rhinological and Otological Society, Inc. Sentinel Lymph Node Status is the Most Important Prognostic Factor in Patients With Melanoma of the Scalp

More information

Rebecca Vogel, PGY-4 March 5, 2012

Rebecca Vogel, PGY-4 March 5, 2012 Rebecca Vogel, PGY-4 March 5, 2012 Historical Perspective Changes In The Staging System Studies That Started The Talk Where We Go From Here Cutaneous melanoma has become an increasingly growing problem,

More information

Review Article Lymphoscintigraphy Defines New Lymphatic Pathways from Cutaneous Melanoma Site: Clinical Implications and Surgical Management

Review Article Lymphoscintigraphy Defines New Lymphatic Pathways from Cutaneous Melanoma Site: Clinical Implications and Surgical Management Radiology Research and Practice Volume 2011, Article ID 817043, 5 pages doi:10.1155/2011/817043 Review Article Lymphoscintigraphy Defines New Lymphatic Pathways from Cutaneous Melanoma Site: Clinical Implications

More information

Talk to Your Doctor. Fact Sheet

Talk to Your Doctor. Fact Sheet Talk to Your Doctor Hearing the words you have skin cancer is overwhelming and would leave anyone with a lot of questions. If you have been diagnosed with Stage I or II cutaneous melanoma with no apparent

More information

Patent Blue Dye (P.B.D) tums.ac.ir

Patent Blue Dye (P.B.D)   tums.ac.ir 80-84 1387 2 66 80 : 30 :.. 1385 1382.. Patent Blue Dye (P.B.D). 48 :. - (%47)13 19 195 17.. :.. : * * 88723410 : email: omranipour@ tums.ac.ir. 4 5. Patent Blue Dye (P.B.D) 6-8 %13. %20 1 2. 3 1992 Morton.

More information

Desmoplastic Melanoma: Surgical Management and Adjuvant Therapy

Desmoplastic Melanoma: Surgical Management and Adjuvant Therapy Desmoplastic Melanoma: Surgical Management and Adjuvant Therapy Dale Han, MD Assistant Professor Department of Surgery Section of Surgical Oncology No disclosures Background Desmoplastic melanoma (DM)

More information

Sentinel lymph node (SLN) biopsy is a wellestablished

Sentinel lymph node (SLN) biopsy is a wellestablished ORIGINAL ARTICLE DISCORDANT LYMPHATIC DRAINAGE PATTERNS REVEALED BY SERIAL LYMPHOSCINTIGRAPHY IN CUTANEOUS HEAD AND NECK MALIGNANCIES Alliric I. Willis, MD, John A. Ridge, MD, PhD Department of Surgical

More information

Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy

Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy American Academy of Dermatology 2018 Annual Meeting San Diego, CA, February 17, 2018 Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy Christopher Bichakjian,

More information

Therapeutic Lymph Node Dissection in Melanoma: Different Prognosis for Different Macrometastasis Sites?

Therapeutic Lymph Node Dissection in Melanoma: Different Prognosis for Different Macrometastasis Sites? Ann Surg Oncol (01) 19:91 91 DOI.14/s44-01-401- ORIGINAL ARTICLE MELANOMAS Therapeutic Lymph Node Dissection in Melanoma: Different Prognosis for Different Macrometastasis Sites? K. P. Wevers, MD, E. Bastiaannet,

More information

J Clin Oncol 34: by American Society of Clinical Oncology INTRODUCTION

J Clin Oncol 34: by American Society of Clinical Oncology INTRODUCTION VOLUME 34 NUMBER 10 APRIL 1, 2016 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating

More information

Melanoma Quality Reporting

Melanoma Quality Reporting Melanoma Quality Reporting September 1, 2013 December 31, 2016 Laurence McCahill, MD Surgical Oncologist Metro Health Surgical Oncology Metro Health Professional Building 2122 Health Drive SW Wyoming,

More information

Nodal staging in localized melanoma. The experience of the Brescia Melanoma Unit

Nodal staging in localized melanoma. The experience of the Brescia Melanoma Unit The British Association of Plastic Surgeons (2003) 56, 534 539 Nodal staging in localized melanoma. The experience of the Brescia Melanoma Unit Giorgio Manca a, *, Fabio Facchetti b, Claudio Pizzocaro

More information

Sentinel Lymph Node Biopsies in Cutaneous Melanoma: A systematic review of the literature. Sasha Jenkins

Sentinel Lymph Node Biopsies in Cutaneous Melanoma: A systematic review of the literature. Sasha Jenkins Sentinel Lymph Node Biopsies in Cutaneous Melanoma: A systematic review of the literature By Sasha Jenkins A Master s Paper submitted to the faculty of the University of North Carolina at Chapel Hill in

More information

University of Groningen

University of Groningen University of Groningen Nodular Histologic Subtype and Ulceration are Tumor Factors Associated with High Risk of Recurrence in Sentinel Node-Negative Melanoma Patients Faut, Marloes; Wevers, Kevin; van

More information

LYMPHATIC DRAINAGE PATTERNS OF HEAD AND NECK CUTANEOUS MELANOMA OBSERVED ON LYMPHOSCINTIGRAPHY AND SENTINEL LYMPH NODE BIOPSY

LYMPHATIC DRAINAGE PATTERNS OF HEAD AND NECK CUTANEOUS MELANOMA OBSERVED ON LYMPHOSCINTIGRAPHY AND SENTINEL LYMPH NODE BIOPSY LYMPHATIC DRAINAGE PATTERNS OF HEAD AND NECK CUTANEOUS MELANOMA OBSERVED ON LYMPHOSCINTIGRAPHY AND SENTINEL LYMPH NODE BIOPSY Doris Lin, MD, 1 Benjamin L. Franc, MD, 2 Mohammed Kashani-Sabet, MD, 3 Mark

More information

Disclosures. SLNB for Melanoma 25/02/2014 SENTINEL LYMPH NODE BIOPSY FOR MELANOMA: CURRENT GUIDELINES AND THEIR CLINICAL APPLICATION

Disclosures. SLNB for Melanoma 25/02/2014 SENTINEL LYMPH NODE BIOPSY FOR MELANOMA: CURRENT GUIDELINES AND THEIR CLINICAL APPLICATION 8 th Canadian Melanoma Conference February 22, 2014 Rimrock Resort Hotel, Banff, Alberta SENTINEL LYMPH NODE BIOPSY FOR MELANOMA: CURRENT GUIDELINES AND THEIR CLINICAL APPLICATION Christopher Bichakjian,

More information

Cutaneous Melanoma: Epidemiology (USA) The Sentinel Node in Head and Neck Melanoma. Cutaneous Melanoma: Epidemiology (USA)

Cutaneous Melanoma: Epidemiology (USA) The Sentinel Node in Head and Neck Melanoma. Cutaneous Melanoma: Epidemiology (USA) The Sentinel Node in Head and Neck Melanoma Cutaneous Melanoma: Epidemiology (USA) 6 th leading cause of cancer among men and women 68,720 new cases of invasive melanoma in 2009 8,650 deaths from melanoma

More information

After primary tumor treatment, 30% of patients with malignant

After primary tumor treatment, 30% of patients with malignant ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant

More information

PAPER. Interval Sentinel Lymph Nodes in Melanoma

PAPER. Interval Sentinel Lymph Nodes in Melanoma PAPER Interval Sentinel Lymph Nodes in Melanoma Kelly M. McMasters, MD, PhD; Celia Chao, MD; Sandra L. Wong, MD; William R. Wrightson, MD; Merrick I. Ross, MD; Douglas S. Reintgen, MD; R. Dirk Noyes, MD;

More information

Sentinel Lymph Node Biopsy for Head and Neck Cutaneous Melanoma

Sentinel Lymph Node Biopsy for Head and Neck Cutaneous Melanoma Sentinel Lymph Node Biopsy for Head and Neck Cutaneous Melanoma S. Ross Patton, MD - PGY III Faculty Mentor: Susan McCammon, MD The University of Texas Medical Branch (UTMB Health) Department of Otolaryngology

More information

ORIGINAL ARTICLE. (SLN) biopsy is revolutionizing

ORIGINAL ARTICLE. (SLN) biopsy is revolutionizing ORIGINAL ARTICLE Management of Malignant Melanoma of the Head and Neck Using Dynamic Lymphoscintigraphy and Gamma Probe Guided Sentinel Lymph Node Biopsy Grant W. Carlson, MD; Douglas R. Murray, MD; Robert

More information

ORIGINAL ARTICLE. Patterns of Recurrence in Patients With Melanoma After Radical Lymph Node Dissection

ORIGINAL ARTICLE. Patterns of Recurrence in Patients With Melanoma After Radical Lymph Node Dissection ORIGINAL ARTICLE Patterns of Recurrence in Patients With Melanoma After Radical Lymph Node Dissection Nir Nathansohn, MD, MHA; Jacob Schachter, MD; Haim Gutman, MD Hypothesis: Previous interventions (excisional

More information

Lymph node ratio is an important and independent prognostic factor for patients with stage III melanoma.

Lymph node ratio is an important and independent prognostic factor for patients with stage III melanoma. Thomas Jefferson University Jefferson Digital Commons Department of Surgery Faculty Papers Department of Surgery 1-1-2012 Lymph node ratio is an important and independent prognostic factor for patients

More information

Topics for Discussion. Malignant Melanoma. Surgical Treatment. Current Treatment of Cutaneous Melanoma 5/17/2013. Lymph Regional nodes:

Topics for Discussion. Malignant Melanoma. Surgical Treatment. Current Treatment of Cutaneous Melanoma 5/17/2013. Lymph Regional nodes: Topics for Discussion What is a sentinel lymph node (SLN)? Utility of sentinel lymph biopsies: therapeutic or staging? Current Treatment of Cutaneous Melanoma Carlos Corvera, M.D. Associate Professor of

More information

Research Article Prediction of Sentinel Node Status and Clinical Outcome in a Melanoma Centre

Research Article Prediction of Sentinel Node Status and Clinical Outcome in a Melanoma Centre Skin Cancer Volume 2013, Article ID 904701, 7 pages http://dx.doi.org/10.1155/2013/904701 Research Article Prediction of Sentinel Node Status and Clinical Outcome in a Melanoma Centre Vera Teixeira, 1

More information

Recurrence of cutaneous melanoma of the head and neck after negative sentinel lymph node biopsy

Recurrence of cutaneous melanoma of the head and neck after negative sentinel lymph node biopsy ORIGINAL ARTICLE Recurrence of cutaneous melanoma of the head and neck after negative sentinel lymph node biopsy Melinda V. Davis Malesevich, MD, 1 Ryan Goepfert, MD, 2 Mark Kubik, MD, 1 Dianna B. Roberts,

More information

What Is a Sentinel Node? Re-Evaluating the 10% Rule for Sentinel Lymph Node Biopsy in Melanoma

What Is a Sentinel Node? Re-Evaluating the 10% Rule for Sentinel Lymph Node Biopsy in Melanoma Journal of Surgical Oncology 2007;95:623 628 What Is a Sentinel Node? Re-Evaluating the 10% Rule for Sentinel Lymph Node Biopsy in Melanoma HIDDE M. KROON, MD, 1 LORI LOWE, MD, 2 SANDRA WONG, MD, 1 DOUG

More information

Melanoma Surgery Update James R. Ouellette, DO FACS Premier Health Cancer Institute Wright State University Chief, Surgical Oncology Division

Melanoma Surgery Update James R. Ouellette, DO FACS Premier Health Cancer Institute Wright State University Chief, Surgical Oncology Division Melanoma Surgery Update 2018 James R. Ouellette, DO FACS Premier Health Cancer Institute Wright State University Chief, Surgical Oncology Division Surgery for Melanoma Mainstay of treatment for potentially

More information

Melanoma. Kaushik Mukherjee MD A. Scott Pearson MD

Melanoma. Kaushik Mukherjee MD A. Scott Pearson MD Melanoma Kaushik Mukherjee MD A. Scott Pearson MD Disclosures You still have to study Not all inclusive No Western blots Extensive use of Google Image Search and Sabiston Melanoma Basics 8 th most common

More information

Nodal Treatment in Melanoma: Snow to MSLT-II

Nodal Treatment in Melanoma: Snow to MSLT-II Nodal Treatment in Melanoma: Snow to MSLT-II Mark B. Faries, MD, FACS Director, Donald L. Morton Melanoma Research Program Program Director, JWCI Complex General Surgical Oncology Fellowship Director,

More information

Contradiction of Clinical Expectations in Lymphoscintigraphy Sentinel Node Mapping in Detecting Microscopic Melanoma Metastasis

Contradiction of Clinical Expectations in Lymphoscintigraphy Sentinel Node Mapping in Detecting Microscopic Melanoma Metastasis Case Report 474 Contradiction of Clinical Expectations in Lymphoscintigraphy Sentinel Node Mapping in Detecting Microscopic Melanoma Metastasis John WC Chang, MD; Hsui-Fong Chiang, RN; Yung-Feng Lo 1,

More information

Sentinel Node Localisation of Melanoma

Sentinel Node Localisation of Melanoma Sentinel Node Localisation of Melanoma V Bongers, Diakonessenhuis, Utrecht 1. Introduction A melanoma is mostly a malignancy of the skin. The sentinel lymph node (SLN) concept of sequential progression

More information

Controversies and Questions in the Surgical Treatment of Melanoma

Controversies and Questions in the Surgical Treatment of Melanoma Controversies and Questions in the Surgical Treatment of Melanoma Giorgos C. Karakousis, M.D. Assistant Professor of Surgery Division of Endocrine and Oncologic Surgery University of Pennsylvania School

More information

Melanoma of the Skin

Melanoma of the Skin 24 Melanoma of the Skin C44.0 Skin of lip, NOS C44.1 Eyelid C44.2 External ear C44.3 Skin of other and unspecified parts of face C44.4 Skin of scalp and neck C44.5 Skin of trunk C44. Skin of upper limb

More information

Kentaro Tanaka, 1 Hiroki Mori, 1 Mutsumi Okazaki, 1 Aya Nishizawa, 2 and Hiroo Yokozeki Introduction. 2. Case Presentation

Kentaro Tanaka, 1 Hiroki Mori, 1 Mutsumi Okazaki, 1 Aya Nishizawa, 2 and Hiroo Yokozeki Introduction. 2. Case Presentation Case Reports in Oncological Medicine Volume 2013, Article ID 259326, 4 pages http://dx.doi.org/10.1155/2013/259326 Case Report Long-Term Treatment Outcome after Only Popliteal Lymph Node Dissection for

More information

Melanoma of the Skin INTRODUCTION SUMMARY OF CHANGES

Melanoma of the Skin INTRODUCTION SUMMARY OF CHANGES 24 Melanoma of the Skin C44.0 Skin of lip, NOS C44.1 Eyelid C44.2 External ear C44.3 Skin of other and unspecified parts of face C44.4 Skin of scalp and neck C44.5 Skin of trunk C44.6 Skin of upper limb

More information

ORIGINAL ARTICLE. Reliability of Sentinel Lymph Node Mapping With Biopsy for Head and Neck Cutaneous Melanoma

ORIGINAL ARTICLE. Reliability of Sentinel Lymph Node Mapping With Biopsy for Head and Neck Cutaneous Melanoma ORIGINAL ARTICLE Reliability of Sentinel Lymph Node Mapping With Biopsy for Head and Neck Cutaneous Melanoma Cecelia E. Schmalbach, MD; Brian Nussenbaum, MD; Riley S. Rees, MD; Jennifer Schwartz, MD; Timothy

More information

Surgery for Melanoma and What s on the Horizon

Surgery for Melanoma and What s on the Horizon and What s on the Horizon Giorgos C. Karakousis, M.D. Assistant Professor of Surgery Perelman School of Medicine at the University of Pennsylvania Background/Overview 76,870 cases of melanoma estimated

More information

Precision Surgery for Melanoma

Precision Surgery for Melanoma Precision Surgery for Melanoma Giorgos C. Karakousis, M.D. Assistant Professor of Surgery Perelman School of Medicine at the University of Pennsylvania Background 87,110 cases of melanoma estimated in

More information

Thin Melanoma with Nodal Involvement: Analysis of Demographic, Pathologic, and Treatment Factors with Regard to Prognosis

Thin Melanoma with Nodal Involvement: Analysis of Demographic, Pathologic, and Treatment Factors with Regard to Prognosis Ann Surg Oncol DOI 10.1245/s10434-016-5646-9 ORIGINAL ARTICLE MELANOMAS Thin Melanoma with Nodal Involvement: Analysis of Demographic, Pathologic, and Treatment Factors with Regard to Prognosis Giorgos

More information

Surgical Issues in Melanoma

Surgical Issues in Melanoma Surgical Issues in Melanoma Mark B. Faries, MD, FACS Director, Donald L. Morton Melanoma Research Program Director, Surgical Oncology Training Program Professor of Surgery John Wayne Cancer Institute Surgical

More information

Long-Term Survival Analysis and Clinical Follow-Up in Acral Lentiginous Malignant Melanoma Undergoing Sentinel Lymph Node Biopsy in Korean Patients

Long-Term Survival Analysis and Clinical Follow-Up in Acral Lentiginous Malignant Melanoma Undergoing Sentinel Lymph Node Biopsy in Korean Patients Ann Dermatol Vol. 26, No. 2, 2014 http://dx.doi.org/10.5021/ad.2014.26.2.177 ORIGINAL ARTICLE Long-Term Survival Analysis and Clinical Follow-Up in Acral Lentiginous Malignant Melanoma Undergoing Sentinel

More information

Time Course and Pattern of Metastasis of Cutaneous Melanoma Differ between Men and Women

Time Course and Pattern of Metastasis of Cutaneous Melanoma Differ between Men and Women Time Course and Pattern of Metastasis of Cutaneous Melanoma Differ between Men and Women Liljana Mervic 1,2 * 1 Department of Dermatology, Center of Dermatooncology, University of Tüebingen, Germany, 2

More information

Clinical Practice Guidelines

Clinical Practice Guidelines Clinical Practice Guidelines Clinical Practice Guidelines for Melanoma Douglas Reintgen, MD, et al H. Lee Moffitt Cancer Center & Research Institute These clinical practice guidelines for melanoma have

More information

Morphological characteristics of the primary tumor and micrometastases in sentinel lymph nodes as a predictor of melanoma progression

Morphological characteristics of the primary tumor and micrometastases in sentinel lymph nodes as a predictor of melanoma progression Morphological characteristics of the primary tumor and micrometastases in sentinel lymph nodes as a predictor of melanoma progression M.N. Kukushkina, S.I. Korovin, O.I. Solodyannikova, G.G. Sukach, A.Yu.

More information

Michael T. Tetzlaff MD, PhD

Michael T. Tetzlaff MD, PhD American Joint Cancer Committee (AJCC) staging system for primary cutaneous melanoma (8 th Edition) and principles of sentinel lymph node evaluation Emphasis on concise and accurate reporting of primary

More information

Technical Considerations. Imaging Considerations

Technical Considerations. Imaging Considerations 354 CUTANEOUS MALIGNANCY OF THE HEAD AND NECK desmoplastic melanomas are characterized by a uniform desmoplasia that is prominent throughout the entire tumor (termed pure desmoplastic melanoma), whereas

More information

Tumor Mitotic Rate Added to the Equation: Melanoma Prognostic Factors Changed?

Tumor Mitotic Rate Added to the Equation: Melanoma Prognostic Factors Changed? Ann Surg Oncol (2015) 22:2978 2987 DOI 10.1245/s10434-014-4349-3 ORIGINAL ARTICLE MELANOMAS Tumor Mitotic Rate Added to the Equation: Melanoma Prognostic Factors Changed? A Single-Institution Database

More information

Index. Note: Page numbers of article titles are in boldface type. A Age as factor in melanoma, Anorectal melanoma RT for, 1035

Index. Note: Page numbers of article titles are in boldface type. A Age as factor in melanoma, Anorectal melanoma RT for, 1035 Index Note: Page numbers of article titles are in boldface type. A Age as factor in melanoma, 947 948 Anorectal melanoma RT for, 1035 B Bacille Calmette-Guerin (BCG) in melanoma, 1008 BCG. See Bacille

More information

Prognosis of Sentinel Node Staged Patients with Primary Cutaneous Melanoma

Prognosis of Sentinel Node Staged Patients with Primary Cutaneous Melanoma Prognosis of Sentinel Node Staged Patients with Primary Cutaneous Melanoma Otmar Elsaeßer 1., Ulrike Leiter 1 *., Petra G. Buettner 2, Thomas K. Eigentler 1, Friedegund Meier 1, Benjamin Weide 1, Gisela

More information

Impact of Prognostic Factors

Impact of Prognostic Factors Melanoma Prognostic Factors: where we started, where are we going? Impact of Prognostic Factors Staging Management Surgical intervention Adjuvant treatment Suraj Venna, MD Assistant Clinical Professor,

More information

Protocol applies to melanoma of cutaneous surfaces only.

Protocol applies to melanoma of cutaneous surfaces only. Melanoma of the Skin Protocol applies to melanoma of cutaneous surfaces only. Procedures Biopsy (No Accompanying Checklist) Excision Re-excision Protocol revision date: January 2005 Based on AJCC/UICC

More information

Poor Outcomes in Head and Neck Non-Melanoma Cutaneous Carcinomas

Poor Outcomes in Head and Neck Non-Melanoma Cutaneous Carcinomas 10 The Open Otorhinolaryngology Journal, 2011, 5, 10-14 Open Access Poor Outcomes in Head and Neck Non-Melanoma Cutaneous Carcinomas Kevin C. Huoh and Steven J. Wang * Head and Neck Surgery and Oncology,

More information

Clinical Case Conference Melanoma

Clinical Case Conference Melanoma Clinical Case Conference Melanoma Epidemiology ~60,000 cases and 8,000 deaths per year in US Caucasian:African American = 10:1 15% arise from existing nevi 91% are cutaneous 15% are LN+ at presentation

More information

Popliteal lymph node dissection for metastases of cutaneous malignant melanoma

Popliteal lymph node dissection for metastases of cutaneous malignant melanoma Teixeira et al. World Journal of Surgical Oncology 2014, 12:135 WORLD JOURNAL OF SURGICAL ONCOLOGY CASE REPORT Open Access Popliteal lymph node dissection for metastases of cutaneous malignant melanoma

More information

Primary Cutaneous Melanoma Pathology Reporting Proforma DD MM YYYY. *Tumour site. *Specimen laterality. *Specimen type

Primary Cutaneous Melanoma Pathology Reporting Proforma DD MM YYYY. *Tumour site. *Specimen laterality. *Specimen type Primary Cutaneous Melanoma Pathology Reporting Proforma Includes the International Collaboration on Cancer reporting dataset denoted by * Family name Given name(s) Date of birth DD MM YYYY Sex Male Female

More information

Epithelial Cancer- NMSC & Melanoma

Epithelial Cancer- NMSC & Melanoma Epithelial Cancer- NMSC & Melanoma David Chin MB, BCh, BAO, LRCP, LRCS (Ireland) MCh(MD), PhD (UQ), FRCS, FRACS (Plast) Plastic & Reconstructive Surgeon Visiting Scientist Melanoma Genomic Group & Drug

More information

Clinical Study Mucosal Melanoma in the Head and Neck Region: Different Clinical Features and Same Outcome to Cutaneous Melanoma

Clinical Study Mucosal Melanoma in the Head and Neck Region: Different Clinical Features and Same Outcome to Cutaneous Melanoma ISRN Dermatology Volume 2013, Article ID 586915, 5 pages http://dx.doi.org/10.1155/2013/586915 Clinical Study Mucosal Melanoma in the Head and Neck Region: Different Clinical Features and Same Outcome

More information

Lessons Learned From the Sunbelt Melanoma Trial

Lessons Learned From the Sunbelt Melanoma Trial Journal of Surgical Oncology 2004;86:212 223 Lessons Learned From the Sunbelt Melanoma Trial KELLY M. McMASTERS, MD, PhD, 1 * R. DIRK NOYES, MD, 2 DOUGLAS S. REINTGEN, MD, 3 JAMES S. GOYDOS, MD, 4 PETER

More information

NEW SURGICAL APPROACHES TO MELANOMA THERAPY

NEW SURGICAL APPROACHES TO MELANOMA THERAPY NEW SURGICAL APPROACHES TO MELANOMA THERAPY Melanoma 2003: New Insights Into Therapy & Treatment Douglas L. Fraker, M.D. University of Pennsylvania Surgical Treatment of Melanoma Primary resection margins

More information

Aberrant lymphatic drainage and risk for melanoma recurrence after negative sentinel node biopsy in middle-aged and older men

Aberrant lymphatic drainage and risk for melanoma recurrence after negative sentinel node biopsy in middle-aged and older men ORIGINAL ARTICLE Aberrant lymphatic drainage and risk for melanoma recurrence after negative sentinel node biopsy in middle-aged and older men Anthony H. Kaveh, BS, 1 Nicole M. Seminara, MD, 1 Melynda

More information

Results, morbidity, and quality of life of melanoma patients undergoing sentinel lymph node staging Vries, Mattijs de

Results, morbidity, and quality of life of melanoma patients undergoing sentinel lymph node staging Vries, Mattijs de University of Groningen Results, morbidity, and quality of life of melanoma patients undergoing sentinel lymph node staging Vries, Mattijs de IMPORTANT NOTE: You are advised to consult the publisher's

More information

Malignant Melanoma in the Elderly: Different Regional Disease and Poorer Prognosis

Malignant Melanoma in the Elderly: Different Regional Disease and Poorer Prognosis 538 Ivyspring International Publisher Research Paper Journal of Cancer 2011; 2: 538-543 Malignant Melanoma in the Elderly: Different Regional Disease and Poorer Prognosis James B. Macdonald 1, Amylou C.

More information

Clinico-pathological Features of Patients with Melanoma and Positive Sentinel Lymph Node Biopsy: A Single Institution Experience

Clinico-pathological Features of Patients with Melanoma and Positive Sentinel Lymph Node Biopsy: A Single Institution Experience 2015;23(2):122-129 CLINICAL ARTICLE Clinico-pathological Features of Patients with Melanoma and Positive Sentinel Lymph Node Biopsy: A Single Institution Experience Damir Homolak 1, Mirna Šitum 2,3, Hrvoje

More information

Radionuclide detection of sentinel lymph node

Radionuclide detection of sentinel lymph node Radionuclide detection of sentinel lymph node Sophia I. Koukouraki Assoc. Professor Department of Nuclear Medicine Medicine School, University of Crete 1 BACKGROUND The prognosis of malignant disease is

More information

Melanoma Underwriting Presented at 2018 AHOU Conference. Hank George FALU

Melanoma Underwriting Presented at 2018 AHOU Conference. Hank George FALU Melanoma Underwriting Presented at 2018 AHOU Conference Hank George FALU MELANOMA EPIDEMIOLOGY 70-80,000 American cases annually Majority are in situ or thin > 20% are diagnosed age 45 8-9,000 melanoma

More information

Katsuhiro Yamada, Natsuko Noguti, Masaaki Tsuda, Hazime Nagato, Naoko Hasunuma, Yoshihiro Umebayashi and Motomu Manabe

Katsuhiro Yamada, Natsuko Noguti, Masaaki Tsuda, Hazime Nagato, Naoko Hasunuma, Yoshihiro Umebayashi and Motomu Manabe Akita J Med 36 : 45-52, 2009 45 Katsuhiro Yamada, Natsuko Noguti, Masaaki Tsuda, Hazime Nagato, Naoko Hasunuma, Yoshihiro Umebayashi and Motomu Manabe (Received 22 December 2008, Accepted 15 January 2009)

More information

Abstract. Background We evaluated the contribution of sentinel-node biopsy to outcomes in patients with newly diagnosed melanoma.

Abstract. Background We evaluated the contribution of sentinel-node biopsy to outcomes in patients with newly diagnosed melanoma. The new england journal of medicine established in 112 september 2, 6 vol. 355 no. 13 Sentinel-Node Biopsy or Nodal in Melanoma Donald L. Morton, M.D., John F. Thompson, M.D., Alistair J. Cochran, M.D.,

More information

Clinical utilities and biological characteristics of melanoma sentinel lymph nodes

Clinical utilities and biological characteristics of melanoma sentinel lymph nodes W J C O World Journal of Clinical Oncology Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.5306/wjco.v7.i2.174 World J Clin Oncol 2016 April

More information

Surgical Margins in Cutaneous Melanoma (2 cm Versus 5 cm for Lesions Measuring Less Than 2.1-mm Thick)

Surgical Margins in Cutaneous Melanoma (2 cm Versus 5 cm for Lesions Measuring Less Than 2.1-mm Thick) 1941 Surgical Margins in Cutaneous Melanoma (2 cm Versus 5 cm for Lesions Measuring Less Than 2.1-mm Thick) Long-Term Results of a Large European Multicentric Phase III Study David Khayat, M.D., Ph.D.

More information

ORIGINAL ARTICLE. Cervical Sentinel Lymph Node Biopsy for Melanomas of the Head and Neck and Upper Thorax

ORIGINAL ARTICLE. Cervical Sentinel Lymph Node Biopsy for Melanomas of the Head and Neck and Upper Thorax ORIGINAL ARTICLE Cervical Sentinel Lymph Node Biopsy for Melanomas of the Head and Neck and Upper Thorax Jeffrey D. Wagner, MD; Hee-Myung Park, MD; John J. Coleman III, MD; Charlene Love, RN; John T. Hayes,

More information

AJCC 8 Implementation January 1, 2018 Melanoma of the Skin. Suraj Venna

AJCC 8 Implementation January 1, 2018 Melanoma of the Skin. Suraj Venna AJCC 8 Implementation January 1, 2018 Melanoma of the Skin Suraj Venna Personalized Medicine AJCC 8 th Edition This Time It s Personal Traditional AJCC (TNM) population-based analyses of large databases

More information

Racial differences in six major subtypes of melanoma: descriptive epidemiology

Racial differences in six major subtypes of melanoma: descriptive epidemiology Wang et al. BMC Cancer (2016) 16:691 DOI 10.1186/s12885-016-2747-6 RESEARCH ARTICLE Racial differences in six major subtypes of melanoma: descriptive epidemiology Yu Wang 1, Yinjun Zhao 2 and Shuangge

More information

An estimated 76,690 patients will be diagnosed with invasive

An estimated 76,690 patients will be diagnosed with invasive SONDAK ET AL Evidence-Based Clinical Practice Guidelines on the Use of Sentinel Lymph Node Biopsy in Melanoma Vernon K. Sondak, MD, Sandra L. Wong, MD, Jeffrey E. Gershenwald, MD, and John F. Thompson,

More information

Molecular Enhancement of Sentinel Node Evaluation

Molecular Enhancement of Sentinel Node Evaluation Cochran Illustrations 060104 Molecular Enhancement of Sentinel Node Evaluation Alistair Cochran, MD and Rong Huang MD Departments of Pathology and Laboratory Medicine and Surgery, David Geffen School of

More information

Sentinel Node Alphabet Soup: MSLT-1, DeCOG-SLT, MSLT-2, UNC

Sentinel Node Alphabet Soup: MSLT-1, DeCOG-SLT, MSLT-2, UNC Sentinel Node Alphabet Soup: MSLT-1, DeCOG-SLT, MSLT-2, UNC David W. Ollila MD James and Jesse Millis Professor of Surgery University of North Carolina, Chapel Hill Disclosures: None July 15, 2018 AJCC

More information

WHAT DOES THE PATHOLOGY REPORT MEAN?

WHAT DOES THE PATHOLOGY REPORT MEAN? Melanoma WHAT IS MELANOMA? Melanoma is a type of cancer that affects cells called melanocytes. These cells are found mainly in skin but also in the lining of other areas such as nose and rectum, and also

More information

Work-up/Follow-up: Baseline and Surveillance Studies for Cutaneous Melanoma Patients

Work-up/Follow-up: Baseline and Surveillance Studies for Cutaneous Melanoma Patients 2018 AAD Annual Meeting, San Diego, CA Work-up/Follow-up: Baseline and Surveillance Studies for Cutaneous Melanoma Patients Susan M. Swetter, MD, FAAD Professor of Dermatology Director, Pigmented Lesion

More information

Analysis of Lymph Nodal Metastases in Malignant Melanoma Using the Poisson Probability Paradigm and Bayes Rule

Analysis of Lymph Nodal Metastases in Malignant Melanoma Using the Poisson Probability Paradigm and Bayes Rule Anatomic Pathology / POISSON PARADIGM AND METASTATIC MELANOMA Analysis of Lymph Nodal Metastases in Malignant Melanoma Using the Poisson Probability Paradigm and Bayes Rule Robin T. Vollmer, MD Key Words:

More information

Advances in Surgical Management of Primary Melanoma: Identifying Patients Who Need More than Conventional Wide Local Excision

Advances in Surgical Management of Primary Melanoma: Identifying Patients Who Need More than Conventional Wide Local Excision Advances in Surgical Management of Primary Melanoma: Identifying Patients Who Need More than Conventional Wide Local Excision Christopher J. Miller, MD Director of Penn Dermatology Oncology Center Associate

More information

Update on 8 th Edition Cutaneous AJCC Staging of Primary Cutaneous Melanoma. Michael T. Tetzlaff MD, PhD

Update on 8 th Edition Cutaneous AJCC Staging of Primary Cutaneous Melanoma. Michael T. Tetzlaff MD, PhD Update on 8 th Edition Cutaneous AJCC Staging of Primary Cutaneous Melanoma Michael T. Tetzlaff MD, PhD Associate Professor Departments of Pathology (Dermatopathology) and Translational and Molecular Pathology

More information

Predictive Factors for the Positivity of the Sentinel Lymph Node in Malignant Melanoma

Predictive Factors for the Positivity of the Sentinel Lymph Node in Malignant Melanoma ORIGINAL RESEARCH SURGERY // ANATOMO-PATHOLOGY Predictive Factors for the Positivity of the Sentinel Lymph Node in Malignant Melanoma Călin Crăciun, Orsolya Hankó- Bauer, Zalán Benedek, Sorin Sorlea, Marius

More information

NAACCR Webinar Series 1

NAACCR Webinar Series 1 Collecting Cancer Data: Melanoma 2013 2014 NAACCR Webinar Series April 3, 2014 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching

More information

Sentinel Lymph Node Biopsy for Breast Cancer

Sentinel Lymph Node Biopsy for Breast Cancer Sentinel Lymph Node Biopsy for Breast Cancer Registrar Tutorial Adam Cichowitz Surgical Registrar The Royal Melbourne Hospital Sentinel Lymph Node Biopsy Axillary LN status important prognostic factor

More information

Position Statement on Management of the Axilla in Patients with Invasive Breast Cancer

Position Statement on Management of the Axilla in Patients with Invasive Breast Cancer - Official Statement - Position Statement on Management of the Axilla in Patients with Invasive Breast Cancer Sentinel lymph node (SLN) biopsy has replaced axillary lymph node dissection (ALND) for the

More information

When Do I Consider Myself Cured?

When Do I Consider Myself Cured? The Melanoma Patient Symposium - Science to Survivorship When Do I Consider Myself Cured? 26 September 2009 Jeffrey E. Gershenwald, MD, FACS Professor of Surgery, Dept. of Surgical Oncology Professor,

More information

Sentinel Lymph Node Biopsy Is Valuable For All Cancer. Surgery Grand Rounds Debate October 6, 2008 Joel Baumgartner

Sentinel Lymph Node Biopsy Is Valuable For All Cancer. Surgery Grand Rounds Debate October 6, 2008 Joel Baumgartner Sentinel Lymph Node Biopsy Is Valuable For All Cancer Surgery Grand Rounds Debate October 6, 2008 Joel Baumgartner History Lymphatics first described by Rasmus Bartholin in 1653 Rudolf Virchow postulated

More information

PAPER. Is Completion Lymphadenectomy After a Positive Sentinel Lymph Node Biopsy for Cutaneous Melanoma Always Necessary?

PAPER. Is Completion Lymphadenectomy After a Positive Sentinel Lymph Node Biopsy for Cutaneous Melanoma Always Necessary? PAPER Is Completion Lymphadenectomy After a Positive Sentinel Lymph Node Biopsy for Cutaneous Melanoma Always Necessary? Nahel Elias, MD; Kenneth K. Tanabe, MD; Arthur J. Sober, MD; Michele A. Gadd, MD;

More information

An Overview of Melanoma. Harriet Kluger, M.D. Associate Professor Section of Medical Oncology Yale Cancer Center

An Overview of Melanoma. Harriet Kluger, M.D. Associate Professor Section of Medical Oncology Yale Cancer Center An Overview of Melanoma Harriet Kluger, M.D. Associate Professor Section of Medical Oncology Yale Cancer Center Melanoma Statistics Median age at presentation 45-55 55 years Incidence: 2003 54,200 cases

More information

Melanoma Patients and the Sentinel Lymph Node (SLN) Procedure: An Oncologic Surgeon s Perspective

Melanoma Patients and the Sentinel Lymph Node (SLN) Procedure: An Oncologic Surgeon s Perspective Melanoma Patients and the Sentinel Lymph Node (SLN) Procedure: An Oncologic Surgeon s Perspective Giorgos C. Karakousis, M.D. Associate Professor of Surgery Hospital of the University of Pennsylvania Disclosures

More information

Management of Head and Neck Melanoma

Management of Head and Neck Melanoma Management of Head and Neck Melanoma 3 James H F Shaw and Michael Fay Auckland Hospital, Great Mercury Island New Zealand 1. Introduction The incidence of melanoma in New Zealand (NZ) is one of the highest

More information